Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Cipla
Cantor Fitzgerald
US Department of Justice
Harvard Business School
Farmers Insurance
Cerilliant
Federal Trade Commission
Chinese Patent Office
McKesson

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,394,405

« Back to Dashboard

Which drugs does patent 8,394,405 protect, and when does it expire?


Patent 8,394,405 protects ORACEA and is included in one NDA. There has been one Paragraph IV challenge on Oracea.

This patent has twelve patent family members in seven countries.

Summary for Patent: 8,394,405

Title:Once daily formulations of tetracyclines
Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
Inventor(s): Chang; Rong-Kun (Rockville, MD), Raoufinia; Arash (Springfield, VA), Shah; Niraj (Owings Mills, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:12/926,932
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Galderma Labs Lp
ORACEA
doxycycline
CAPSULE;ORAL050805-001May 26, 2006RXYesYes► Subscribe► SubscribeY TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,394,405

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,709,478Once daily formulations of tetracyclines► Subscribe
7,749,532Once daily formulations of tetracyclines► Subscribe
8,394,406Once daily formulations of tetracyclines► Subscribe
8,470,364Once daily formulations of tetracyclines► Subscribe
8,206,740Once daily formulations of tetracyclines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,394,405

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2521885► Subscribe
Canada2803922► Subscribe
Canada2894736► Subscribe
Denmark1615622► Subscribe
Denmark2204168► Subscribe
European Patent Office1615622► Subscribe
European Patent Office2204168► Subscribe
Spain2391385► Subscribe
Spain2534827► Subscribe
Japan2006522162► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
Teva
McKesson
Moodys
Colorcon
Medtronic
Novartis
Daiichi Sankyo
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot